Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.

ABSTRACT:

Introduction

The degree and duration of response to epidermal growth factor receptor (EGFR) inhibitors in EGFR mutated lung cancer are heterogeneous. We hypothesized that the concurrent genomic landscape of these tumors, which is currently unknown in view of the prevailing single gene assay diagnostic paradigm in clinical practice, could play a role in clinical outcomes and/or mechanisms of resistance.

Methods

We retrospectively probed our institutional lung cancer database for tumors with EGFR kinase domain mutations that were also evaluated by more comprehensive molecular profiling, and evaluated tumor response to EGFR tyrosine kinase inhibitors (TKIs).

Results

Out of 171 EGFR mutated tumor-patient cases, 20 were sequenced using at least a limited comprehensive geno

SUBMITTER: VanderLaan PA 

PROVIDER: S-EPMC5351777 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature